Neurocrine Biosciences Stock Net Income
| NBIX Stock | USD 138.89 2.90 2.13% |
Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 249.7 M | 262.2 M | |
| Net Income From Continuing Ops | 191 M | 200.6 M | |
| Net Income Applicable To Common Shares | 177.7 M | 186.6 M | |
| Net Income Per Share | 2.56 | 2.68 | |
| Net Income Per E B T | 0.75 | 0.87 |
Neurocrine | Net Income |
Neurocrine Biosciences Company Net Income Analysis
Neurocrine Biosciences' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Neurocrine Biosciences Net Income | 249.7 M |
Most of Neurocrine Biosciences' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neurocrine Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurocrine Biosciences is extremely important. It helps to project a fair market value of Neurocrine Stock properly, considering its historical fundamentals such as Net Income. Since Neurocrine Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurocrine Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurocrine Biosciences' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neurocrine Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Neurocrine Biosciences reported net income of 249.7 M. This is 26.83% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 56.27% higher than that of the company.
Neurocrine Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.Neurocrine Biosciences is currently under evaluation in net income category among related companies.
Neurocrine Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Neurocrine Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurocrine Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurocrine Biosciences' value.| Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.4 M | Dodge & Cox | 2023-12-31 | 1.3 M | Dsm Capital Partners Llc | 2023-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.2 M | Deerfield Management Co | 2023-09-30 | 1.2 M | Wellington Management Company Llp | 2023-12-31 | 1.2 M | Rock Springs Capital Management Lp | 2023-12-31 | 1.2 M | Brown Advisory Holdings Inc | 2023-12-31 | 1.1 M | Armistice Capital, Llc | 2023-12-31 | 1 M | Blackrock Inc | 2023-12-31 | 13.6 M | Vanguard Group Inc | 2023-12-31 | 9.7 M |
Neurocrine Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 12.96 B | ||||
| Shares Outstanding | 100.58 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 94.71 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | 202.90 X | ||||
| Price To Book | 6.07 X | ||||
| Price To Sales | 7.18 X | ||||
| Revenue | 1.89 B | ||||
| Gross Profit | 1 B | ||||
| EBITDA | 416.1 M | ||||
| Net Income | 249.7 M | ||||
| Cash And Equivalents | 799.4 M | ||||
| Cash Per Share | 8.31 X | ||||
| Total Debt | 428.4 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 22.61 X | ||||
| Cash Flow From Operations | 389.9 M | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | 2.48 X | ||||
| Price To Earnings To Growth | 0.44 X | ||||
| Target Price | 153.29 | ||||
| Number Of Employees | 1.4 K | ||||
| Beta | 0.28 | ||||
| Market Capitalization | 13.68 B | ||||
| Total Asset | 3.25 B | ||||
| Retained Earnings | (157.1 M) | ||||
| Working Capital | 952.2 M | ||||
| Current Asset | 384.07 M | ||||
| Current Liabilities | 25.71 M | ||||
| Net Asset | 3.25 B |
About Neurocrine Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Neurocrine Biosciences Investors Sentiment
The influence of Neurocrine Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Neurocrine. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Neurocrine Biosciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurocrine Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurocrine Biosciences' short interest history, or implied volatility extrapolated from Neurocrine Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Neurocrine Biosciences Piotroski F Score and Neurocrine Biosciences Altman Z Score analysis. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.48 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.